What is 64x Bio?
64x Bio operates at the intersection of synthetic biology and industrial biomanufacturing. The company provides an end-to-end platform specifically engineered for the design and optimization of scalable therapeutic systems. By focusing on the foundational elements of cell line engineering, 64x Bio enables its clients to overcome traditional bottlenecks in the production of complex biologics. Their market position is defined by a commitment to high-throughput, data-driven methodologies that enhance the efficiency and reliability of therapeutic development pipelines. As the industry shifts toward more personalized and complex medicine, 64x Bio's technological framework offers a necessary bridge between laboratory-scale research and commercial-scale manufacturing.
How much funding has 64x Bio raised?
64x Bio has raised a total of $55M across 1 funding round:
Series A
$55M
Series A (2022): $55M with participation from Lifeforce Capital Gp I and Northpond Ventures
Key Investors in 64x Bio
Lifeforce Capital Gp I
A venture capital firm specializing in identifying and scaling software-driven companies within the healthcare and life sciences sectors.
Northpond Ventures
A prominent venture capital firm focused on science-driven investments, particularly in the fields of biotechnology, life sciences, and advanced technology.
What's next for 64x Bio?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the company's technical infrastructure and deepening its research capabilities. With the backing of institutional investors, 64x Bio is expected to prioritize the commercialization of its platform, potentially entering into new partnerships with global pharmaceutical entities. The focus will remain on refining its cell line engineering processes to meet the rigorous demands of clinical-grade production. By maintaining a trajectory of rapid innovation, the company aims to set new benchmarks for scalability and precision in the biomanufacturing landscape, ultimately reducing the time-to-market for next-generation therapeutic products.
See full 64x Bio company page
